An Observational Study on Teriflunomide-exposed Pregnancies
Completed · NCT03198351
Conditions: Multiple Sclerosis
At a glance
- Research payments reported, 2025
- $3,780
- U.S. investigators named
- 0
- Sites paid
- 1
- Planned or actual enrollment
- 220
About the trial
- Sponsor
- Sanofi
- Tested
- Teriflunomide (HMR1726) (drug)
- Dates
- Started 2013-04-25; completion 2023-06-13
- Results posted
- Not yet
Primary Objective: To evaluate any potential increase in the risk of major birth defects, in the first year of life, in teriflunomide-exposed pregnancies. Secondary Objective: To evaluate the potential effect of teriflunomide-exposure on other adverse pregnancy outcomes including any potential pattern of minor birth defects, spontaneous abortion, stillbirth, preterm delivery, small for gestational age at birth and at 1 year follow-up.
From ClinicalTrials.gov, last updated 2023-08-28. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Genzyme Corporation reported $3,780 in research payments for this study in 2025 (1 payments).
Products named: Aubagio
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.